Press 
Releases 

Validates platform for new class of liquid biopsy: multiomic disease biology of living cells from a chosen tissue, starting with the liver

Programme builds on existing US footprint and strengthens EvoLiver’s path to US clinical adoption

AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease

Organ-specific, AI-ready multi-omics platform validated for liver disease diagnostics and monitoring

Reflects the potential of EvoLiver™ test to improve early liver cancer detection among high-risk patients